Clinical trialsCompany release

ALX Oncology reports $147.2M cash, with ALX2004 Phase 1 data due in December

🇺🇸 Alx Oncology Holdings Inc (ALXO) · Mon 16 Nov 2026

The US biotech posted a $21.8 million third-quarter net loss and says its cash runway extends into the first half of 2028.

ALX Oncology reported third-quarter 2026 results on 16 November, showing a net loss of $21.8 million. The company ended the period with $147.2 million in cash and investments, which it says is enough to fund operations into the first half of 2028.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Alx Oncology Holdings Inc ↗

Article written by VigiEye from the official source (Alx Oncology Holdings Inc). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →